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Serum CrAg LA 98-100% 98-100%
Serum CrAg EIA 93-95% 96-100%
CSF CrAg LA 97%-99% 99%
CSF CrAg EIA 100% 98-100%
Cryptococcal infection is an infection caused by encapsulated yeasts of the 
Cryptococcus fungi that primarily manifests in the CNS or lungs in 
immunocompromised hosts. Our case describes disseminated Cryptococcus 
neoformans infection and cerebral cryptococcoma in an immunocompetent 
individual. 
History
• A 64 year-old male with no pertinent medical history presented to his 
PCP for worsening headaches for the past 2 months.
• MRI: new ring enhancing lesion of the left thalamus
• CT chest: bilateral upper lobe tree-in-bud nodules and a right upper 
lobe nodule with stippled calcification. 
• Lung biopsy, complicated by pneumothorax, was unremarkable. 
• 2 days later developed headaches and nausea, became non-verbal, 
and exhibited seizure activity. Had to be intubated and sedated after 
this and taken to ICU.
Physical Exam
• Lungs: Clear.
• Neuro: Does not follow commands. Opens eyes spontaneously but not 
to verbal stimuli. PERRL. Face appears symmetrical. Withdraws to pain 
in all extremities. Moves all 4 limbs spontaneously.
Labs
• Leukocytosis: 16.6: 88.8% neutrophils, 4.5% lymphocytes, 
• HIV negative
• CSF: WBC 107, glucose 23, protein 79, opening pressure 23
• Cryptococcal neoformans Ag, serum EIA positive
• Cryptococcal neoformans Ag, CSF EIA positive
• CSF culture: Cryptococcus neoformans
Management
• Started on amphotericin B and flucytosine.
• 1 week after treatment repeat MRI brain showed improvement of the 
lesion, presumed to be cryptoccoma.
• Required multiple LPs and drain placement due to increased ICP 
causing agitation and altered mental status that improved with CSF 
drainage.
• Patient improved and discharged on 18 months of fluconazole.
• C. neoformans should still be in the considered as potential 
diagnosis for patient with altered mental status, regardless 
of immune status.
• Patients can have normal radiological findings.
• Consider early serum CrAg testing to expedite diagnosis.
• Cryptococcomas are rare.
• Treatment duration can be up to 20 months, especially for 
cryptococcomas.
• Monitoring and reducing intracranial pressures may be key 
components of care.
C. neoformans C. gattii
Location: Worldwide, in soil, 
trees, bird droppings
Subtropical and tropical 
regions + British 


















Treatment: Amphotericin B + flucytosine, followed by 
fluconazole
The most widely used tests for cryptococcus diagnosis are cryptococcal 
polysaccharide capsular antigen (CrAg) with either latex agglutination (LA) or 
enzyme immunoassay (EIA).
